Cardio Diagnostics Holdings Inc (CDIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CDIO market cap for the company's overall valuation and market capitalisation.
Cardio Diagnostics Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cardio Diagnostics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their cash flow conversion efficiency. See CDIO debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OurLiving AB
ST:OURLIV
|
-4.139x |
|
Till Capital Ltd
V:TIL
|
-0.014x |
|
Bank Danamon Indonesia Tbk
JK:BDMN
|
0.048x |
|
Future Market Networks Limited
NSE:FMNL
|
0.072x |
|
IMPRENDIROMA S.P.A.
F:Y37
|
N/A |
|
SG COMPANY S.P.A.
F:7KZ
|
N/A |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
-0.019x |
|
Rathdowney Resources Ltd
V:RTH
|
0.013x |
Annual Cash Flow Conversion Efficiency for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. View current stock price of Cardio Diagnostics Holdings Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.97 Million | $-5.73 Million | -0.821x | -57.20% |
| 2024-12-31 | $9.56 Million | $-4.99 Million | -0.522x | +72.76% |
| 2023-12-31 | $2.96 Million | $-5.67 Million | -1.917x | -62.02% |
| 2022-12-31 | $4.30 Million | $-5.09 Million | -1.183x | -115.97% |
| 2021-12-31 | $1.07 Million | $-585.29K | -0.548x | -227.92% |
| 2020-12-31 | $60.37K | $25.86K | 0.428x | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more